ClinicalTrials.gg
CompletedNCT01008696Updated Aug 13, 2013Results posted

An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis

A Phase 4 interventional study of Rabeprazole and Lansoprazole in Reflux Esophagitis, sponsored by Janssen Korea, Ltd., Korea. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-08-13.

Sponsored by Janssen Korea, Ltd., Korea (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
217
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to compare the treatment effects of rabeprazole and lansoprazole depending on the genotyping (process of determining the genetic constitution) of CYP2C19 in treating reflux esophagitis (caused by gastroesophageal reflux; deterioration of the protective lining on the inner wall of the lower esophagus); and to evaluate the cure rate of reflux esophagitis on endoscopy (a thin flexible tube with a microscopic camera at the end which is passed down your throat into the esophagus, stomach, and duodenum) after treatment with rabeprazole and lansoprazole.

Read the detailed description

This is a prospective (study following participants forward in time), open-label (all people know the identity of the intervention), multi-center (conducted in more than 1 center), randomized (study drug assigned by chance) study in participants with reflux esophagitis. The study will include 4 visits: Visit 1 (Screening period of up to 14 days), Visit 2 (Day 1), Visit 3 (Day 29+3), and Visit 4 (Day 56). After Screening, eligible participants will be analyzed on Visit 2 (Day 1) for symptoms during past week, At visit 3 (Day 29+3) participants will be randomly assigned to 1 of the 2 treatment groups: rabeprazole 20 milligram (mg) or lansoprazole 30 mg group. Participants will receive rabeprazole 20 mg tablet orally once daily for 28 to 56 days or lansoprazole 30 mg capsule orally once daily for 28 to 56 days. A post-study follow-up visit will be conducted only if participant will be affected by any serious adverse event within 30 days after the completion of study drug. Participants will primarily be assessed for the cure rate of reflux esophagitis based on endoscopy of 2 groups. Participants' safety will be monitored throughout the study.

02

Conditions studied

  • Reflux Esophagitis

Browse trials for

Keywords

  • Reflux esophagitis
  • Rabeprazole
  • Lansoprazole
03

In context

Esophagitis, Peptic

83 studies on the registry are indexed under Esophagitis, Peptic; 16 are open to participants now.

This study's enrollment of 217 is above the median of 135 across 60 interventional studies indexed under Esophagitis, Peptic.

Browse Esophagitis, Peptic studies →

Lead sponsor

Janssen Korea, Ltd., Korea is the lead sponsor of 79 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants diagnosed with reflux esophagitis of Grade A or higher by Los Angeles (LA) classification based on the endoscopy among participants complaining of gastroesophageal reflux symptoms (such as: Heartburn, regurgitation, globus sensation, chronic [lasting a long time] cough [sudden, loud flow if air from the lungs], epigastric [area above the navel] pain, non-cardiac chest pain, hoarseness, or dysphagia), or those who diagnosed with reflux esophagitis of Grade B or higher without complaining of symptoms
  • Participants without other serious disease except the study indication (reflux esophagitis)
  • Participants with hematology (related to blood) panel, serum chemistry panel, or urinalysis result clinically within twice the normal range
  • Female Participants of who are using the appropriate or with a negative urine pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Participants with other serious gastrointestinal disease except reflux esophagitis (example: digestive tract cancer [abnormal tissue that grows and spreads in the body until it kills], hepatic disease, pancreatic disease, and ulcer. However, the scar of an ulcer is included in study targets
  • Participants with other serious concomitant disease(s) such as renal disorder, cerebrovascular disease, cardiovascular disease, hepatic disease, and severe respiratory disease
  • Participants with medical history of upper gastrointestinal tract surgery, esophagostenosis, or a chalasia
  • Participants with hematology panel, serum chemistry panel, or urinalysis result of above twice the normal range
  • Participants who cannot discontinue proton pump inhibitors or Histamine 2 antagonist which may have influence on the study, 4 weeks before the start of this clinical study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
217 participants (actual)

Study arms

  • Experimental
    Rabeprazole

    Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.

    Drug: Rabeprazole

  • Active comparator
    Lansoprazole

    Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.

    Drug: Lansoprazole

Interventions

  • Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.

  • Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Completely Cured of Reflux Esophagitis Evaluated by Endoscopy Based on CYP2C19

    Reflux esophagitis evaluated by endoscopy as per LA Classification graded as: A=1 or more mucosal breaks no longer than 5 millimeter (mm) that did not extend between tops of 2 mucosal folds, B=1 or more mucosal breaks more than 5 mm long that did not extend between tops of 2 mucosal folds, C=1 or more mucosal break continuous between the tops of 2 or more mucosal folds but involves less than 75 percent of circumference, D=1 or more mucosal break involving at least 75 percent of circumference. Participants that were not categorized in any of the above mentioned grades (A to D) were considered as cured of reflux esophagitis. Participants were classified as CYP2C19 homozygous extensive, heterozygous extensive and poor metabolizers.

    Time frame: Day 57

Secondary outcomes

  1. Change From Baseline in Symptoms of Reflux Esophagitis Evaluated by the Symptom Assessment Questionnaire

    Gastroesophageal reflux disease and abdominal GI-related symptoms (heartburn, regurgitation, globus sensation, chronic cough, epigastric pain, non cardiac chest pain, hoarseness, dysphagia, abdominal distension, bloating, post-prandial discomfort, early satiety, nausea, vomiting, belching) experienced by participants were assessed and graded into 4 categories: 0 (Nothing)=No symptom, 1 (Mild)=A little but not uncomfortable, 2 (Moderate)=Present but interfering daily life activities a little, 3 (Severe)=Very uncomfortable, interfering daily life activities or sleeping.

    Time frame: Baseline and Day 57

  2. Overall Assessment of Study Medication by Investigator

    Investigator's overall assessment of study medication based on the global symptom assessment was measured. The assessment was categorized as: 2=very good, 1=good, 0=as usual, -1=bad and -2=very bad.

    Time frame: Day 57

07

Results

Posted Aug 13, 2013

Participant flow

Participant flow — Overall Study
MilestoneRabeprazoleLansoprazole
Started108109
Completed9192
Not completed1717
Withdrew: Participant's evasion of hospital visit54
Withdrew: Withdrawal by subject24
Withdrew: Physician decision51
Withdrew: Adverse event10
Withdrew: Participants' non-cooperation23
Withdrew: Other23
Withdrew: Other02

Outcome measures

PrimaryPercentage of Participants Completely Cured of Reflux Esophagitis Evaluated by Endoscopy Based on CYP2C19

Reflux esophagitis evaluated by endoscopy as per LA Classification graded as: A=1 or more mucosal breaks no longer than 5 millimeter (mm) that did not extend between tops of 2 mucosal folds, B=1 or more mucosal breaks more than 5 mm long that did not extend between tops of 2 mucosal folds, C=1 or more mucosal break continuous between the tops of 2 or more mucosal folds but involves less than 75 percent of circumference, D=1 or more mucosal break involving at least 75 percent of circumference. Participants that were not categorized in any of the above mentioned grades (A to D) were considered as cured of reflux esophagitis. Participants were classified as CYP2C19 homozygous extensive, heterozygous extensive and poor metabolizers.

Time frame:
Day 57
Reported as:
Number · Percentage of participants
Percentage of Participants Completely Cured of Reflux Esophagitis Evaluated by Endoscopy Based on CYP2C19
Percentage of participantsRabeprazoleLansoprazole
Homozygous Extensive Metabolizer (n=42, 35)97.3793.94
Heterozygous Extensive Metabolizer (n=30, 38)100.00100.00
Poor Metabolizer (n=15, 18)93.33100.00
Statistical analysis
  • Rabeprazole vs Lansoprazole · Chi-squared · p = 0.8849 (Homozygous extensive metabolizer)
  • Rabeprazole vs Lansoprazole · Chi-squared · p = 0.8650 (Heterozygous extensive metabolizer)
  • Rabeprazole vs Lansoprazole · Chi-squared · p = 0.2660 (Poor metabolizer)
SecondaryChange From Baseline in Symptoms of Reflux Esophagitis Evaluated by the Symptom Assessment Questionnaire

Gastroesophageal reflux disease and abdominal GI-related symptoms (heartburn, regurgitation, globus sensation, chronic cough, epigastric pain, non cardiac chest pain, hoarseness, dysphagia, abdominal distension, bloating, post-prandial discomfort, early satiety, nausea, vomiting, belching) experienced by participants were assessed and graded into 4 categories: 0 (Nothing)=No symptom, 1 (Mild)=A little but not uncomfortable, 2 (Moderate)=Present but interfering daily life activities a little, 3 (Severe)=Very uncomfortable, interfering daily life activities or sleeping.

Time frame:
Baseline and Day 57
Reported as:
Mean · Units on a scale
Change From Baseline in Symptoms of Reflux Esophagitis Evaluated by the Symptom Assessment Questionnaire
Units on a scaleRabeprazoleLansoprazole
Baseline: Heartburn (n=87, 91)0.61 ± 0.840.59 ± 0.89
Baseline:Regurgitation (n=87, 91)0.98 ± 0.930.93 ± 0.96
Baseline: Globus sensation (n=87, 91)0.55 ± 0.820.82 ± 0.78
Baseline: Chronic cough (n=87, 91)0.34 ± 0.700.30 ± 0.66
Baseline: Epigastric pain (n=87, 90)0.91 ± 1.000.94 ± 0.95
Baseline: Non cardiac chest pain (n=85, 90)0.33 ± 0.710.26 ± 0.66
Baseline: Hoarseness (n=87, 90)0.23 ± 0.540.22 ± 0.54
Baseline: Dysphagia (n=87, 91)0.16 ± 0.500.22 ± 0.57
Baseline: Abdominal distension (n=87, 91)0.61 ± 0.840.59 ± 0.80
Baseline: Bloating (n=87, 90)0.55 ± 0.820.44 ± 0.75
Baseline: Post-prandial discomfort (n=87, 91)0.53 ± 0.780.55 ± 0.76
Baseline: Early satiety (n=86, 91)0.27 ± 0.580.25 ± 0.55
Baseline: Nausea (n=87, 91)0.16 ± 0.480.13 ± 0.37
Baseline: Vomiting (n=87, 91)0.08 ± 0.380.02 ± 0.15
Baseline: Belching (n=87, 91)0.38 ± 0.700.36 ± 0.62
Change at Day 57: Heartburn (n=87, 91)-0.55 ± 0.83-0.54 ± 0.90
Change at Day 57: Regurgitation (n=87, 91)-0.89 ± 0.93-0.84 ± 0.95
Change at Day 57: Globus sensation (n=87, 91)-0.31 ± 0.69-0.32 ± 0.66
Change at Day 57: Chronic cough (n=87, 91)-0.22 ± 0.64-0.21 ± 0.61
Change at Day 57: Epigastric pain (n=87, 90)-0.77 ± 0.95-0.77 ± 0.92
Change at Day 57:Non cardiac chest pain (n=85, 90)-0.28 ± 0.65-0.20 ± 0.54
Change at Day 57: Hoarseness (n=87, 90)-0.14 ± 0.51-0.17 ± 0.55
Change at Day 57: Dysphagia (n=87, 91)-0.11 ± 0.44-0.14 ± 0.48
Change at Day 57: Abdominal distension (n=87, 91)-0.38 ± 0.80-0.40 ± 0.76
Change at Day 57: Bloating (n=87, 90)-0.41 ± 0.72-0.37 ± 0.69
Change at Day57:Post-prandial discomfort (n=87,91)-0.45 ± 0.73-0.35 ± 0.74
Change at Day 57: Early satiety (n=86, 91)-0.21 ± 0.49-0.16 ± 0.58
Change at Day 57: Nausea (n=87, 91)-0.16 ± 0.48-0.11 ± 0.38
Change at Day 57: Vomiting (n=87, 91)-0.08 ± 0.38-0.02 ± 0.15
Change at Day 57: Belching (n=87, 91)-0.25 ± 0.70-0.29 ± 0.54
Statistical analysis
  • Rabeprazole vs Lansoprazole · Wilcoxon rank-sum test · p = 0.7734 (Change at Day 57: Heartburn)
  • Rabeprazole vs Lansoprazole · Wilcoxon rank-sum test · p = 0.6414 (Change at Day 57: Regurgitation)
  • Rabeprazole vs Lansoprazole · Wilcoxon rank-sum test · p = 0.7809 (Change at Day 57: Globus sensation)
  • Rabeprazole vs Lansoprazole · Wilcoxon rank-sum test · p = 0.8294 (Change at Day 57: Chronic cough)
  • Rabeprazole vs Lansoprazole · Wilcoxon rank-sum test · p = 0.9874 (Change at Day 57: Epigastric pain)
  • Rabeprazole vs Lansoprazole · Wilcoxon rank-sum test · p = 0.2776 (Change at Day 57: Non cardiac chest pain)
  • Rabeprazole vs Lansoprazole · Wilcoxon rank-sum test · p = 0.6295 (Change at Day 57: Hoarseness)
  • Rabeprazole vs Lansoprazole · Wilcoxon rank-sum test · p = 0.5335 (Change at Day 57: Dysphagia)
  • Rabeprazole vs Lansoprazole · Wilcoxon rank-sum test · p = 0.8068 (Change at Day 57: Abdominal distension)
  • Rabeprazole vs Lansoprazole · Wilcoxon rank-sum test · p = 0.5680 (Change at Day 57: Bloating)
  • Rabeprazole vs Lansoprazole · Wilcoxon rank-sum test · p = 0.5913 (Change at Day 57: Post-prandial discomfort)
  • Rabeprazole vs Lansoprazole · Wilcoxon rank-sum test · p = 0.5566 (Change at Day 57: Early satiety)
  • Rabeprazole vs Lansoprazole · Wilcoxon rank-sum test · p = 0.7047 (Change at Day 57: Nausea)
  • Rabeprazole vs Lansoprazole · Wilcoxon rank-sum test · p = 0.3654 (Change at Day 57: Vomitting)
  • Rabeprazole vs Lansoprazole · Wilcoxon rank-sum test · p = 0.5310 (Change at Day 57: Belching)
SecondaryOverall Assessment of Study Medication by Investigator

Investigator's overall assessment of study medication based on the global symptom assessment was measured. The assessment was categorized as: 2=very good, 1=good, 0=as usual, -1=bad and -2=very bad.

Time frame:
Day 57
Reported as:
Mean · Units on a scale
Overall Assessment of Study Medication by Investigator
Units on a scaleRabeprazoleLansoprazole
Overall Assessment of Study Medication by Investigator1.37 ± 0.711.43 ± 0.74
Statistical analysis
  • Rabeprazole vs Lansoprazole · Wilcoxon rank-sum test · p = 0.5032

Adverse events

Collected over Baseline up to Day 57. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rabeprazole—2/108 (1.9%)42/108 (38.9%)
Lansoprazole—0/109 (0%)42/109 (38.5%)
Most frequent serious events
Most frequent serious events
EventRabeprazoleLansoprazole
Diabetes mellitusMetabolism and nutrition disorders1/1080/109
Haemorrhoid operationSurgical and medical procedures1/1080/109
Most frequent other events
Showing 10 of 13
Most frequent other events
EventRabeprazoleLansoprazole
Abdominal distensionGastrointestinal disorders19/10818/109
CoughRespiratory, thoracic and mediastinal disorders18/10815/109
Abdominal painGastrointestinal disorders12/10817/109
Sensation of foreign bodyGeneral disorders13/10816/109
DyspepsiaGastrointestinal disorders10/10815/109
Abdominal pain upperGastrointestinal disorders9/10812/109
Early satietyGeneral disorders11/10811/109
DysphagiaGastrointestinal disorders10/10810/109
DysphoniaRespiratory, thoracic and mediastinal disorders9/1089/109
NauseaGastrointestinal disorders8/1089/109

Baseline characteristics

Baseline characteristics were measured for full analysis set (FAS) population. It included participants who received study medication at least once and had follow-up data that could be used after Baseline among participants who met eligibility criteria. Last observation carried forward (LOCF) was used.

Age Continuous
Age Continuous(Years)RabeprazoleLansoprazoleTotal
Mean49.70 ± 11.7249.74 ± 12.6549.72 ± 12.17
Sex: Female, Male
Sex: Female, Male(Participants)RabeprazoleLansoprazoleTotal
Female122234
Male7569144
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 5 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2009
First posted
Nov 6, 2009
Start
May 2007
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Results first posted
Aug 13, 2013
Last update
Aug 13, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01008696
Responsible party
Sponsor
First posted
Nov 6, 2009
Start date
May 2007
Primary completion
Aug 2008
Completion
Aug 2008
Results posted
Aug 13, 2013
Last update
Aug 13, 2013

Study contacts

Janssen Korea, Ltd., Korea Clinical Trial
study director · Janssen Korea, Ltd., Korea

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion